调强放疗联合同步化疗治疗不可切除或残留的非间变性甲状腺癌
回顾性分析88例不可切除或大体残留的非间变性、非髓样甲状腺癌患者,接受根治性调强放疗(IMRT)者中51.1%同步多柔比星化疗。同步化疗组4年局部无进展生存(85.8% vs 68.8%,p=0.036)和总生存(68.0% vs 47.0%,p=0.043)均优于单纯IMRT,且未显著增加毒性。
要点
- 同步多柔比星化疗与更优的局部控制和总生存相关。
- 同步化疗未显著增加3级以上急性或晚期毒性。
- IMRT是安全有效的局部控制手段,可考虑同步化疗。
核心结论
- IMRT对不可切除或未完全切除的非间变性、非髓样甲状腺癌是安全有效的局部控制手段。
- 同步多柔比星未增加毒性,且可能改善局部控制和总生存,应考虑使用。
研究设计与样本
- 回顾性研究,纳入2000至2015年间88例接受根治性IMRT的大体残留或不可切除的非间变性、非髓样甲状腺癌患者。
- 45例(51.1%)接受同步化疗(CC-IMRT),43例(48.9%)接受单纯IMRT。
- 所有CC-IMRT患者接受每周多柔比星10 mg/m2。
主要发现
- 全部患者4年局部无进展生存(LPFS)为77.3%。
- CC-IMRT组4年LPFS高于单纯IMRT组(85.8% vs 68.8%,p=0.036)。
- 全部患者4年总生存(OS)为56.3%。
- CC-IMRT组4年OS高于单纯IMRT组(68.0% vs 47.0%,p=0.043)。
- 多因素分析显示同步化疗与较低死亡风险(HR 0.395,p=0.019)和较低局部失败风险(HR 0.306,p=0.042)相关。
关键数值与推荐
- 3级及以上急性毒性发生率为23.9%,最常见为皮炎(18.2%)和黏膜炎(9.1%)。
- 17.1%的患者在放疗期间或结束后不久需要经皮内镜下胃造瘘(PEG),10.1%在放疗后超过12个月仍需PEG。
- CC-IMRT组急性和晚期毒性发生率无统计学显著升高,但皮炎和PEG需求有升高趋势。
临床怎么用
- 对于不可切除或大体残留的非间变性、非髓样甲状腺癌,可考虑根治性IMRT联合同步多柔比星化疗以改善局部控制和生存。
- 同步化疗时需关注皮炎和PEG需求等毒性趋势,但总体毒性未显著增加。
局限性
- 回顾性研究设计。
- 样本量较小(88例)。
- 单中心数据可能限制普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiated thyroid cancer typically has an indolent clinical course but can cause significant morbidity by local progression. Oncologic surgical resection can be technically difficult due to the proximity to critical normal structures in the neck. Our objective was to review the safety, feasibility, and outcomes of definitive-intent intensity-modulated radiation therapy (IMRT) and to analyze whether patients receiving concurrent chemotherapy (CC-IMRT) had higher rates of disease control and survival over IMRT alone in patients with unresectable or gross residual disease (GRD). METHODS: Eighty-eight patients with GRD or unresectable nonanaplastic, nonmedullary thyroid cancer treated with definitive-intent IMRT between 2000 and 2015 were identified. Local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and overall survival (OS) were evaluated using the Kaplan-Meier method. Univariate and multivariate analyses using cox regression were used to determine the impact of clinical conditions and treatment on LPFS, DMFS, and OS. RESULTS: Of the 88 patients identified, 45 (51.1%) were treated CC-IMRT and 43 (48.9%) were treated with IMRT alone. All patients treated with CC-IMRT received weekly doxorubicin (10 mg/m2). The median follow-up among surviving patients was 40.3 months and 29.2 months for all patients. The LPFS at 4 years was 77.3%. Patients receiving CC-IMRT had higher LPFS compared with IMRT alone (CC-IMRT 85.8% vs. IMRT 68.8%, p = 0.036). The 4-year OS was 56.3% for all patients. Patients treated with CC-IMRT had higher OS compared to patients treated with IMRT alone (CC-IMRT 68.0% vs. IMRT 47.0%, p = 0.043). On multivariate analysis, receipt of concurrent chemotherapy was associated with a lower risk of death (HR 0.395, p = 0.019) and lower risk of local failure (HR 0.306, p = 0.042). Grade 3+ acute toxicities occurred in 23.9% of patients, the most frequent being dermatitis (18.2%) and mucositis (9.1%). 17.1% of patients required a percutaneous endoscopic gastrostomy (PEG) tube during or shortly after completion of RT, with 10.1% of patients needing a PEG more than 12 months after therapy. The rates of acute and late toxicities were not statistically higher in the CC-IMRT cohort, although trends towards higher toxicity in the CC-IMRT were present for dermatitis and PEG requirement. CONCLUSIONS: IMRT is a safe and effective means to achieve local control in patients with unresectable or incompletely resected nonanaplastic, nonmedullary thyroid cancer. Concurrent doxorubicin was not associated with worse toxicity and should be considered in these patients given its potential to improve local control and overall survival.
引用
- Beckham TH, Romesser PB, Groen AH, et al. Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. Thyroid. 2018. PMID: 30105947. doi:10.1089/thy.2018.0214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。